Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

ProPhase Labs Inc

PRPH
Current price
0.39 USD -0.02 USD (-4.92%)
Last closed 0.43 USD
ISIN US74345W1080
Sector Healthcare
Industry Diagnostics & Research
Exchange NASDAQ
Capitalization 16 377 564 USD
Yield for 12 month -92.21 %
1Y
3Y
5Y
10Y
15Y
PRPH
21.11.2021 - 28.11.2021

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular and DNA testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. Address: 711 Stewart Avenue, Garden City, NY, United States, 11530

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

18.50 USD

P/E ratio

Dividend Yield

Current Year

+44 384 000 USD

Last Year

+122 647 000 USD

Current Quarter

+3 146 000 USD

Last Quarter

+2 474 000 USD

Current Year

+16 239 000 USD

Last Year

+70 654 000 USD

Current Quarter

-165 000 USD

Last Quarter

-476 000 USD

Key Figures PRPH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -27 014 000 USD
Operating Margin TTM -316.37 %
Price to Earnings
Return On Assets TTM -22.98 %
PEG Ratio
Return On Equity TTM -50.92 %
Wall Street Target Price 18.50 USD
Revenue TTM 17 972 000 USD
Book Value 2.74 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -81.30 %
Dividend Yield
Gross Profit TTM 70 654 000 USD
Earnings per share -1.53 USD
Diluted Eps TTM -1.53 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY -95.20 %
Profit Margin -146.39 %

Dividend Analytics PRPH

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History PRPH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date 24.05.2022
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years 0
Consistent Years 0
Continuous Dividends 1
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 2:1
Payout Ratio
Last Split Date 23.01.1997

Stock Valuation PRPH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 10.09
Enterprise Value Revenue 3.50
Price Sales TTM 0.91
Enterprise Value EBITDA 2.45
Price Book MRQ 0.41

Financials PRPH

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators PRPH

For 52 weeks

0.64 USD 7.48 USD
50 Day MA 1.51 USD
Shares Short Prior Month 245 646
200 Day MA 3.49 USD
Short Ratio 7.04
Shares Short 144 903
Short Percent 0.97 %